Abstract | BACKGROUND: Whether therapeutic drug monitoring (TDM) of infliximab should be implemented in daily practice is an ongoing controversy. AIMS: To assess the real-world use of TDM in an observational multicentre cohort study with consecutive patients with inflammatory bowel disease (IBD) treated with CT-P13. METHODS: Between September 2015 and December 2016, 364 patients with IBD were treated with CT-P13 in 13 gastroenterology departments and were followed up for 54 weeks. Disease activity, CT-P13 trough concentration and anti-CT-P13 antibody (ACA) were recorded. RESULTS:
Steroid-free clinical remission rates at week 54 were 67.0% and 56.4% in patients with CD and UC, respectively. CT-P13 trough concentrations were measured in 70.7% of the patients. The mean CT-P13 trough concentration was 4.2±4.3μg/mL. The presence of ACA was observed in 53 (15.9%) patients. CT-P13 trough concentration was collected in a proactive approach in 62.8% of cases and in a reactive approach in 37.2%. Among patients who submitted to TDM, CT-P13 therapy was optimized in 88.7% of the reactive group and in 22.5% of the proactive group (P<0.001). CONCLUSION: In a real-world cohort of patients with IBD treated with CT-P13, more than two-thirds of the patients underwent TDM. CT-P13 optimization was much less common in the proactive approach than in the reactive approach.
|
Authors | Nicolas Petitdidier, Laurent Beaugerie, Franck Carbonnel, Anne Bourrier, Xavier Treton, Sylvie Rajca, Georgia Malamut, Vered Abitbol, Matthieu Allez, Anne-Laure Pelletier, Lysiane Marthey, Pauline Jouet, Robert Benamouzig, Xavier Amiot, Yoram Bouhnik, Aurelien Amiot |
Journal | Clinics and research in hepatology and gastroenterology
(Clin Res Hepatol Gastroenterol)
Vol. 44
Issue 4
Pg. 609-618
(09 2020)
ISSN: 2210-741X [Electronic] France |
PMID | 31924554
(Publication Type: Journal Article, Observational Study)
|
Copyright | Copyright © 2019 Elsevier Masson SAS. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal
- CT-P13
|
Topics |
- Adult
- Antibodies, Monoclonal
(therapeutic use)
- Cohort Studies
- Drug Monitoring
- Female
- Humans
- Inflammatory Bowel Diseases
(drug therapy)
- Male
- Middle Aged
- Prospective Studies
- Time Factors
|